March 24, 2022
An expert dermatologist evaluates the role of dupilumab in decreasing the clinical burden of severe atopic dermatitis on patients and their caregivers and shares insight on the future outlook of dupilumab in disease management.
Benjamin Lockshin, MD, FAAD, reviews key findings from a phase 2 trial evaluating the safety and efficacy of single-dose dupilumab in children with severe atopic dermatitis.
Benjamin Lockshin, MD, FAAD, comments on the significance of recent expansions of therapeutics options for patients with atopic dermatitis and unmet needs in the field.
